Search

Your search keyword '"Schönland, Stefan"' showing total 7 results
Start Over Author "Schönland, Stefan" Journal british journal of haematology
7 results on '"Schönland, Stefan"'

1. Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019

Author

Swan, Dawn, primary, Hayden, Patrick J., additional, Eikema, Dirk‐Jan, additional, Koster, Linda, additional, Sauer, Sandra, additional, Blaise, Didier, additional, Nicholson, Emma, additional, Rabin, Neil, additional, Touzeau, Cyrille, additional, Byrne, Jennifer, additional, Huynh, Anne, additional, Cornelissen, Jan J., additional, Potter, Victoria, additional, Forcade, Edouard, additional, Parrish, Christopher, additional, Gribben, John, additional, Chretien, Marie‐Lorraine, additional, Mielke, Stephan, additional, Gedde‐Dahl, Tobias, additional, Reményi, Péter, additional, Tsirigotis, Panagiotis, additional, Garcia Guiñón, Antoni, additional, Beksac, Meral, additional, Schönland, Stefan, additional, and Yakoub‐Agha, Ibrahim, additional

Published
2022
Full Text
View/download PDF

2. Submyeloablative total body irradiation‐based conditioning and allogeneic stem cell transplantation in high‐risk myeloma with early progression after up‐front autologous transplantation

Author

Mai, Elias K., primary, Schmitt, Thomas, additional, Radujkovic, Aleksandar, additional, König, Laila, additional, Goldschmidt, Hartmut, additional, Ho, Anthony D., additional, Luft, Thomas, additional, Müller‐Tidow, Carsten, additional, Dreger, Peter, additional, Hegenbart, Ute, additional, and Schönland, Stefan O., additional

Published
2021
Full Text
View/download PDF

3. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow‐up

Author

Basset, Marco, primary, Kimmich, Christoph R., additional, Schreck, Nicholas, additional, Krzykalla, Julia, additional, Dittrich, Tobias, additional, Veelken, Kaya, additional, Goldschmidt, Hartmut, additional, Seckinger, Anja, additional, Hose, Dirk, additional, Jauch, Anna, additional, Müller‐Tidow, Carsten, additional, Benner, Axel, additional, Hegenbart, Ute, additional, and Schönland, Stefan O., additional

Published
2021
Full Text
View/download PDF

4. Submyeloablative total body irradiation‐based conditioning and allogeneic stem cell transplantation in high‐risk myeloma with early progression after up‐front autologous transplantation.

Author

Mai, Elias K., Schmitt, Thomas, Radujkovic, Aleksandar, König, Laila, Goldschmidt, Hartmut, Ho, Anthony D., Luft, Thomas, Müller‐Tidow, Carsten, Dreger, Peter, Hegenbart, Ute, and Schönland, Stefan O.

Subjects
STEM cell transplantation, AUTOTRANSPLANTATION, ACUTE diseases, MULTIPLE myeloma, HEMATOPOIETIC stem cell transplantation, GRAFT versus host disease
Abstract

Finally, other potential treatment options to reduce relapse/progression post alloSCT include post-transplantation cyclophosphamide (ptCy). Keywords: myeloma therapy; stem cell transplantation; cytogenetics EN myeloma therapy stem cell transplantation cytogenetics 244 248 5 12/27/21 20220101 NES 220101 Treatment of patients with relapsed multiple myeloma (MM) after autologous stem cell transplantation (autoSCT) remains challenging. Consequently, a future goal in MM therapy is to combine modern treatment concepts and alloSCT in suitable patients to reduce disease burden and enhance disease control in patients with relapsed high-risk MM. Details on re-induction treatment and response rates prior to alloSCT, engraftment and post alloSCT response rates, maintenance therapy, donor lymphocyte infusions (DLI) and relapse therapies are shown in Table I. The median age at alloSCT was 50 (range 34-64) years. [Extracted from the article]

Published
2022
Full Text
View/download PDF

5. Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic

Author

Kastritis, Efstathios, primary, Wechalekar, Ashutosh, additional, Schönland, Stefan, additional, Sanchorawala, Vaishali, additional, Merlini, Giampaolo, additional, Palladini, Giovanni, additional, Minnema, Monique, additional, Roussel, Murielle, additional, Jaccard, Arnaud, additional, Hegenbart, Ute, additional, Kumar, Shaji, additional, Cibeira, Maria T., additional, Blade, Joan, additional, and Dimopoulos, Meletios A., additional

Published
2020
Full Text
View/download PDF

6. Treosulfan conditioning for allogeneic transplantation in multiple myeloma – improved overall survival in first line haematopoietic stem cell transplantation – a large retrospective study by the Chronic Malignancies Working Party of the EBMT

Author

Gran, Charlotte, primary, Wang, Junfeng, additional, Nahi, Hareth, additional, Koster, Linda, additional, Gahrton, Gösta, additional, Einsele, Herman, additional, Niittyvoupio, Riitta, additional, Edinger, Matthias, additional, Beelen, Dietrich, additional, Ciceri, Fabio, additional, Bornhäuser, Martin, additional, Finke, Jürgen, additional, de Wreede, Liesbeth C., additional, Ljungman, Per, additional, Mielke, Stephan, additional, Tischer, Johanna, additional, Garderet, Laurent, additional, Schönland, Stefan, additional, Yakoub‐Agha, Ibrahim, additional, and Kröger, Nicolaus, additional

Published
2020
Full Text
View/download PDF

7. Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).

Author

Schetelig J, de Wreede LC, Andersen NS, Moreno C, van Gelder M, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Schaap N, Wagner E, Henseler A, van Biezen A, Bornhäuser M, Iacobelli S, Putter H, Schönland SO, and Kröger N

Subjects
Adult, Aged, Delivery of Health Care statistics & numerical data, Europe epidemiology, Female, Humans, Kaplan-Meier Estimate, Karnofsky Performance Status, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Male, Middle Aged, Recurrence, Registries, Retrospective Studies, Risk Factors, Transplantation Conditioning methods, Hematopoietic Stem Cell Transplantation methods, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Professional Practice statistics & numerical data
Abstract

The best approach for allogeneic haematopoietic stem cell transplantations (alloHCT) in patients with chronic lymphocytic leukaemia (CLL) is unknown. We therefore analysed the impact of procedure- and centre-related factors on 5-year event-free survival (EFS) in a large retrospective study. Data of 684 CLL patients who received a first alloHCT between 2000 and 2011 were analysed by multivariable Cox proportional hazards models with a frailty component to investigate unexplained centre heterogeneity. Five-year EFS of the whole cohort was 37% (95% confidence interval [CI], 34-42%). Larger numbers of CLL alloHCTs (hazard ratio [HR] 0·96, P = 0·002), certification of quality management (HR 0·7, P = 0·045) and a higher gross national income per capita (HR 0·4, P = 0·04) improved EFS. In vivo T-cell depletion (TCD) with alemtuzumab compared to no TCD (HR 1·5, P = 0·03), and a female donor compared to a male donor for a male patient (HR 1·4, P = 0·02) had a negative impact on EFS, but not non-myeloablative versus more intensive conditioning. After correcting for patient-, procedure- and centre-characteristics, significant variation in centre outcomes persisted. In conclusion, further research on the impact of centre and procedural characteristics is warranted. Non-myeloablative conditioning appears to be the preferable approach for patients with CLL., (© 2017 John Wiley & Sons Ltd.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results